BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
McKesson
Johnson and Johnson
QuintilesIMS
Citi
Novartis
Chinese Patent Office
US Department of Justice
Fuji
Cerilliant

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019892

« Back to Dashboard

NDA 019892 describes DILAUDID, which is a drug marketed by Fresenius Kabi Usa and Rhodes Pharms and is included in three NDAs. It is available from six suppliers. There is one patent protecting this drug and four Paragraph IV challenges. Additional details are available on the DILAUDID profile page.

The generic ingredient in DILAUDID is hydromorphone hydrochloride. There are fourteen drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the hydromorphone hydrochloride profile page.
Summary for 019892
Tradename:DILAUDID
Applicant:Rhodes Pharms
Ingredient:hydromorphone hydrochloride
Patents:1
Therapeutic Class:Analgesics
Formulation / Manufacturing:see details
Pharmacology for NDA: 019892
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for 019892
Suppliers and Packaging for NDA: 019892
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DILAUDID hydromorphone hydrochloride TABLET;ORAL 019892 NDA AUTHORIZED GENERIC STAT RX USA LLC 16590-774 16590-774-60 60 TABLET in 1 BOTTLE (16590-774-60)
DILAUDID hydromorphone hydrochloride TABLET;ORAL 019892 NDA AUTHORIZED GENERIC STAT RX USA LLC 16590-774 16590-774-30 30 TABLET in 1 BOTTLE (16590-774-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength8MG
Approval Date:Dec 7, 1992TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:Nov 9, 2020Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength4MG
Approval Date:Nov 9, 2007TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:Nov 9, 2020Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2MG
Approval Date:Nov 9, 2007TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:Nov 9, 2020Product Flag?YSubstance Flag?YDelist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Colorcon
Mallinckrodt
US Army
McKinsey
Citi
Fish and Richardson
Cantor Fitzgerald
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot